An IL-7 fusion protein that shows increased thymopoietic ability

Sian M. Henson, Robert Snelgrove, Tracy Hussell, Dominic J. Wells, Richard Aspinall

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)


The role of IL-7 during thymopoiesis has led to it being the focus of a number of therapeutic interventions. However, its small size and pleiotropic nature present problems for thymus-directed therapies. We have created a fusion molecule between the extracellular N-terminal domain of CCR9 and IL-7, which has the potential to overcome these difficulties. This novel fusion protein retains the thymopoietic activity of IL-7 and the ligand-binding ability of CCR9. As a thymopoietic agent, compared with IL-7, it shows an enhanced retention in the thymus, increased de novo T cell production, and increased thymic output Old mice receiving the fusion protein show improved CD8 T cell responses and reduced viral load after infection with influenza virus compared with those receiving IL-7. This chimeric molecule offers a novel therapeutic strategy that may result in the production of an effective immunorestorative agent.

Original languageEnglish
Pages (from-to)4112-4118
Number of pages7
JournalJournal of Immunology
Issue number6
Publication statusPublished - 15 Sept 2005
Externally publishedYes

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'An IL-7 fusion protein that shows increased thymopoietic ability'. Together they form a unique fingerprint.

Cite this